The previous limit increased by 10%, and the two limits increased by 21% in total; Now one limit of the Beijing stock exchange is 30%, and the two limits are 69% in total. Here comes the amazing scene!
The 30cm trading limit of Beijing stock exchange is fierce! Senxuan pharmaceutical has been trading at the 30cm limit for two consecutive days, becoming the first stock with continuous trading limit in the Beijing stock exchange, and Jinghua Pharmaceutical Group Co.Ltd(002349) of the company’s shareholder Shenzhen main board staged six trading limits in seven days.
At the end of the third quarter, senxuan pharmaceutical had 18000 shareholders and 50600 shareholders in Jinghua Pharmaceutical Group Co.Ltd(002349) , totaling nearly 70000.
the first branch of the Beijing stock exchange raised the 30cm limit for two consecutive days
Just half a month ago, after the first 30cm trading limit of the Beijing stock exchange, the 30cm trading limit of the same stock for two consecutive days came again, rising 69% in two days, and the stock rose sharply a few days ago, up 148% in five days. This stock is senxuan medicine of the Beijing stock exchange.
After the sharp rise, senxuan pharmaceutical’s latest closing price was 18.83 yuan, with a total market value of 8 billion yuan.
The covid-19 concept of senxuan medicine is considered to be an important reason for the continuous rise. At present, the epidemic situation in China is grim abroad. Pfizer covid-19 oral drug paxlovid has a good effect and has been authorized by FDA for emergency use. Pfizer oral drug is a combination of pf-07321332 and ritonavir.
In the recent investor interactive Q & A, senxuan pharmaceutical’s parent company Jinghua Pharmaceutical Group Co.Ltd(002349) said that the annual production capacity of its subsidiary senxuan pharmaceutical ritonavir’s main intermediates currently accounts for a high share of the production capacity of such intermediates.
According to the data, senxuan medicine is mainly engaged in the R & D, production and sales of chemical APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates, including anti-tumor APIs, antipyretic, analgesic and anti-inflammatory APIs, anti epilepsy APIs, etc; Pharmaceutical intermediates mainly cover anti AIDS medicine intermediates, antiepileptic drugs intermediates, anti-tumor medicine intermediates, etc. Oxygen containing heterocyclic chemical intermediates mainly include dioxane and dioxane.
clarify that no purchase and sales contract has been signed with Pfizer
Market rumors abound, but on December 30, senxuan pharmaceutical issued an announcement to clarify that it did not have purchase and sales cooperation with Pfizer. The company issued an announcement on the 30th to remind investors that the company has not signed a purchase and sales contract related to ritonavir pharmaceutical intermediates with Pfizer. Investors are invited to invest rationally and pay attention to risks.
Senxuan pharmaceutical said that there are no media reports or market rumors that may or have had a great impact on the stock trading price of the company, involving hot concept matters; Recently, the company’s business situation and internal and external business environment have not changed significantly.
However, the company explained the company’s ritonavir intermediate and Pfizer’s oral drug for covid-19, which are concerned and discussed by investors:
(1) At present, the company produces and sells ritonavir series of pharmaceutical intermediates, and has not yet carried out the production and sales of ritonavir API;
(2) at present, the company has not signed a contract for the purchase and sale of Tonave pharmaceutical intermediates with the Pfizer Inc, and has not supplied any intermediate to the Tonave series. The intermediates sold by the company have been mainly used in the synthesis of the anti AIDS raw material, Tonave, of the Tonave series.
(3) In 2021, the company’s sales volume of ritonavir pharmaceutical intermediates is expected to be 11 tons and the sales revenue is expected to be 16.84 million yuan, with a year-on-year decrease of about 33% and 32% respectively;
(4) From December 1, 2021 to the date of this announcement, the company did not sign large orders related to ritonavir series intermediates, and there were no new customers of this series of products.
hot money speculation as the main
From the seats on the dragon and tiger list, senxuan pharmaceutical’s share price fluctuated sharply recently, mainly due to the trading of securities business department, and few institutional seats participated in the purchase.
received research from e fund and other institutions a month ago
On November 19, senxuan pharmaceutical received research from four institutions, including e fund, Anxin securities, Northeast Securities Co.Ltd(000686) and YueKai securities. At that time, the institutions also paid attention to the specific route of the company’s dioxane products in the field of lithium batteries and the impact of Pfizer covid-19 oral medicine on the company?
The company said that dioxolane products, as the solvent of lithium battery electrolyte, are mainly used in the primary battery field of iron phosphate route; At present, the company’s annual capacity of dioxane is 3000 tons, and the annual capacity after expansion will reach 6000 tons. At present, the equipment installation of the expansion project has been completed and is in the stage of local commissioning. It is expected that the trial production conditions will be available before the end of December.
As for the impact of Pfizer COVID-19 oral medicine, the company said that the products of the company’s ritonavir series intermediates are mainly used in the synthesis of anti AIDS ritonavir raw materials, the dosage of ritonavir in the specific formulation of Pfizer COVID-19, the efficacy of FDA, and the certification of the US, and the selection of Pfizer’s raw material suppliers after mass production. There are uncertainties in the selection of intermediate suppliers by ritonavir API manufacturers. The company will actively participate in and pay close attention to the market and orders.
shareholders Jinghua Pharmaceutical Group Co.Ltd(002349) also rose
Senxuan pharmaceutical holds 72% of the controlling shareholder Jinghua Pharmaceutical Group Co.Ltd(002349) . On the interactive platform, senxuan pharmaceutical actively mentioned the annual production capacity of the main intermediates of ritonavir, which currently occupies a high share in the production capacity of such intermediates. Ritonavir is a component of Pfizer covid-19 oral liquid.
Not only did senxuan pharmaceutical’s share price explode, Jinghua Pharmaceutical Group Co.Ltd(002349) also rose surprisingly, with six trading boards for seven consecutive days.
(China Fund News)
